Correspondence to Dr. Nunzio Bottini, Dept. of Medicine, University of California San Diego, MC0656, La Jolla, CA 92093, USA; nbottini{at}ucsd.edu; Professor Costantino Pitzalis, William Harvey ...

Background: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout. In Phase 1 healthy subject studies, ...

The goal of the Bone and Joint Decade is to improve the health related quality of life for people with musculoskeletal disorders throughout the world. Musculoskeletal disorders are the most common ...

10 Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA 11 Department of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA 12 ...

Correspondence to Dr Zachary Scott Wallace, Division of Rheumatology, Allergy, and Immunology and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General ...

Objective Systemic sclerosis-associated pulmonary arterial hypertension differs from idiopathic pulmonary arterial hypertension with respect to histopathology, treatment responses and survival.

Objectives To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical ...

1 Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2 University of Maryland, Baltimore, Maryland, USA Correspondence to Dr Michelle Petri, Professor of Medicine, Johns Hopkins ...

41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...

Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...

Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...